Company intelligence / Profile preview

OncoTheis

Plan-les-Ouates, Geneva, Switzerland

Ownership: Private
Development stage: Other

Overview

OncoTheis has developed OncoCilAir™, a 3-D human airway/lung cancer in vitro tissue model that enables long-term co-culture of healthy and tumoral cells to study tumor biology, drug resistance, adverse effects, and anti-cancer efficacy; awarded for its impact as an alternative to animal testing and its translational relevance.

Therapeutic areas: Oncology
Modalities: BiologicBioengineered tissueOrganoidIn vitro model
Industry: Non-Drug Biotech

Partnerships

PANVIPREP consortium (participation in European antiviral preparedness network, relevant to broader drug development)

Beyond the preview

Go deeper on OncoTheis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoTheis.

Explore the full profile